Sabrina Pagano

List of Publications by Year
in descending order

50 papers	1,009 citations	430874 18 h-index	454955 30 g-index
52 all docs	52 docs citations	52 times ranked	1195 citing authors

#	Article	IF	Citations
1	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. European Heart Journal, 2011, 32, 412-421.	2.2	110
2	Antiâ€"apolipoprotein Aâ€1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2640-2650.	6.7	90
3	Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. European Heart Journal, 2010, 31, 815-823.	2.2	76
4	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. PLoS ONE, 2020, 15, e0238089.	2.5	71
5	Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thrombosis and Haemostasis, 2013, 109, 706-715.	3.4	48
6	The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinaseâ€"Associated Lipocalin with Progression from CKD to ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2141-2149.	4.5	39
7	Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?. Arthritis Care and Research, 2012, 64, 817-825.	3.4	38
8	Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. Thrombosis and Haemostasis, 2015, 114, 410-422.	3.4	36
9	Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Thrombosis and Haemostasis, 2016, 116, 764-771.	3.4	35
10	Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatology, The, 2022, 4, e11-e13.	3.9	31
11	Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms. Frontiers in Immunology, 2017, 8, 437.	4.8	30
12	18FDG-PET-CT. Stroke, 2014, 45, 3561-3566.	2.0	27
13	Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2342-2349.	2.4	27
14	Definition of Human Apolipoprotein A-I Epitopes Recognized by Autoantibodies Present in Patients with Cardiovascular Diseases. Journal of Biological Chemistry, 2014, 289, 28249-28259.	3.4	26
15	The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?. PLoS ONE, 2015, 10, e0132780.	2.5	26
16	High Prevalence of Antiâ€Apolipoprotein/Aâ€1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage. Therapeutic Apheresis and Dialysis, 2012, 16, 588-594.	0.9	21
17	CD14 as a Mediator of the Mineralocorticoid Receptorâ€"Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology, 2015, 156, 4707-4719.	2.8	20
18	Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis. Thrombosis and Haemostasis, 2016, 116, 554-564.	3.4	20

#	ARTICLE	IF	CITATIONS
19	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. Vascular Pharmacology, 2016, 85, 57-65.	2.1	20
20	Anti-Apolipoprotein A-1 IgG Levels Predict Coronary Artery Calcification in Obese but Otherwise Healthy Individuals. Mediators of Inflammation, 2012, 2012, 1-10.	3.0	18
21	Antiapolipoprotein A-1 IgG Chronotropic Effects Require Nongenomic Action of Aldosterone on L-Type Calcium Channels. Endocrinology, 2012, 153, 1269-1278.	2.8	18
22	Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. Journal of Clinical Medicine, 2019, 8, 1225.	2.4	13
23	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. Journal of Infection, 2018, 76, 186-195.	3.3	12
24	Autoantibodies against apolipoprotein Aâ€1 after COVIDâ€19 predict symptoms persistence. European Journal of Clinical Investigation, 2022, 52, .	3.4	12
25	Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. Hepatology International, 2018, 12, 17-25.	4.2	11
26	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. Journal of Clinical Medicine, 2019, 8, 1002.	2.4	11
27	Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 732.	4.1	11
28	Diagnostic and prognostic value of autoantibodies antiâ€apolipoprotein Aâ€1 and antiâ€phosphorylcholine in acute nonâ€<scp>ST</scp> elevation myocardial infarction. European Journal of Clinical Investigation, 2015, 45, 369-379.	3.4	10
29	Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients. Journal of Clinical Medicine, 2019, 8, 948.	2.4	10
30	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	2.4	10
31	SARSâ€CoVâ€2 infection as a trigger of humoral response against apolipoprotein Aâ€1. European Journal of Clinical Investigation, 2021, 51, e13661.	3.4	10
32	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. Current Pharmaceutical Design, 2019, 25, 3128-3146.	1.9	10
33	Deficiency of Monoacylglycerol Lipase Enhances IgM Plasma Levels and Limits Atherogenesis in a CB2-Dependent Manner. Thrombosis and Haemostasis, 2019, 119, 348-351.	3.4	9
34	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naÃ¯ve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis, 2019, 284, 253-259.	0.8	9
35	Atherosclerotic plaque vulnerability is increased in mouse model of lupus. Scientific Reports, 2020, 10, 18324.	3.3	8
36	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. Vascular Pharmacology, 2015, 71, 84-92.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Prognostic and therapeutic considerations of antibodies against c‐ter apolipoprotein A‐1 in the general population. Clinical and Translational Immunology, 2020, 9, e1220.	3.8	6
38	Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia. Journal of Clinical Medicine, 2022, 11, 105.	2.4	6
39	ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. Journal of Immunological Methods, 2019, 469, 33-41.	1.4	5
40	Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. Rheumatology, 2019, 59, 534-544.	1.9	3
41	Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1?. European Journal of Clinical Investigation, 2021, 52, e13713.	3.4	3
42	Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study. Obesity Surgery, 2022, 32, 355-364.	2.1	3
43	Anti‐ApoA‐1 IgGs predict resistance to waist circumference reduction after Mediterranean diet. European Journal of Clinical Investigation, 2021, 51, e13410.	3.4	2
44	C-Terminus apoA-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formation. Journal of Clinical and Molecular Medicine, 2019, 2, .	0.4	1
45	A9.11‐...Anti-apolipoprotein A1 autoantibodies induce tissue factor activity and expression: a role in atherothrombosis. Annals of the Rheumatic Diseases, 2014, 73, A96.1-A96.	0.9	0
46	Infection-Induced Humoral Autoimmunity. Journal of the American College of Cardiology, 2018, 72, 955-956.	2.8	0
47	Association of novel biomarkers with major clinical outcomes in a cohort of patients with atherosclerotic renovascular disease. Annals of Clinical Biochemistry, 2019, 56, 488-501.	1.6	0
48	Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion. BioMed Research International, 2020, 2020, 1-8.	1.9	0
49	Auto-antibodies against apolipoprotein A-1 block cancer cells proliferation and induce apoptosis. Oncotarget, 2020, 11, 4266-4280.	1.8	0
50	Kinetics of inflammatory biomarkers to predict one-year mortality in older patients hospitalized for pneumonia: a multivariable analysis. International Journal of Infectious Diseases, 2022, 122, 63-69.	3.3	0